Current studies have supported the role of berberine in the treatment of metabolic diseases such as non-alcoholic fatty liver disease, obesity and diabetes, among which the main molecular targets involved include LDLR, AMPK and PPAR [17]. This evidence concerns the gene PPARA and obesity due to melanocortin 4 receptor deficiency.